TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25594360

Group type: EXPERIMENTAL
Intervention: Telenovela intervention (culturally congruent videotaped dramatization with guided dialogue)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telenovela intervention
Number of subjects: 0
Study: 25058107

Group type: EXPERIMENTAL
Intervention: Land Exercise (LE)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Aquatic Exercise (AE)
Number of subjects: 58
Study: 22789796

Group type: EXPERIMENTAL
Intervention: Integrated support programme
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medical care with integrated support programme
Number of subjects: 12

Group type: COMPARATOR
Intervention: Medical care without integrated support programme (Control)
Number of subjects: 12
Study: 19937785

Group type: EXPERIMENTAL
Intervention: Wire-maintaining technique (WMT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional technique (CT)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both WMT and CT
Number of subjects: 103
Study: 17356969

Group type: EXPERIMENTAL
Intervention: Multifaceted program of education and reminders delivered to primary care physicians, mailings and automated telephone calls to patients.
Number of subjects: 241

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 241
Study: 15998890

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg every other day)
Number of subjects: 39876
Study: 11860644

Group type: EXPERIMENTAL
Intervention: Nasal spray administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nasal drop administration
Number of subjects: 10
Study: 10442381

Group type: EXPERIMENTAL
Intervention: UFT (150 mg/m2/day) plus oral calcium folinate (90 mg/day) plus radiotherapy (45 Gy total)
Number of subjects: 11
Study: 7844596

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (AlloBMT)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Chemotherapy (CHEMO)
Number of subjects: 287
Study: 2895592

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Temazepam 20 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg and Temazepam 20 mg
Number of subjects: 100
Study: 30973315

Group type: EXPERIMENTAL
Intervention: Immediate goal‐contingent rewards
Number of subjects: 96

Group type: COMPARATOR
Intervention: Delayed rewards
Number of subjects: 96

Group type: COMPARATOR
Intervention: Immediate goal‐contingent rewards and Delayed rewards
Number of subjects: 96
Study: 30691766

Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 12
Study: 28408697

Group type: EXPERIMENTAL
Intervention: CaHMB with BC30
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CaHMB with placebo
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 26
Study: 26147835

Group type: EXPERIMENTAL
Intervention: Autologous serum (AS) eye drops
Number of subjects: 37

Group type: COMPARATOR
Intervention: Bandage contact lens (BCL)
Number of subjects: 37
Study: 23886213

Group type: EXPERIMENTAL
Intervention: GEMOX regimen (gemcitabine at 1000 mg/m² by fixed-dose rate infusion at 10 mg/m²/min on days 1 and 8, and oxaliplatin at 100 mg/m² on day 1, repeated every 3 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (gemcitabine at 1000 mg/m² by intravenous infusion within 30 min on days 1 and oxaliplatin at 100 mg/m² on day 1, repeated every 3 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 21680632

Group type: EXPERIMENTAL
Intervention: Anonymised information sharing
Number of subjects: 0
Study: 18422779

Group type: EXPERIMENTAL
Intervention: R-MCP (rituximab, mitoxantrone, chlorambucil, and prednisolone)
Number of subjects: 43

Group type: COMPARATOR
Intervention: MCP (mitoxantrone, chlorambucil, and prednisolone)
Number of subjects: 43
Study: 20541220

Group type: EXPERIMENTAL
Intervention: Olanzapine augmentation (olanzapine + divalproex)
Number of subjects: 101
Study: 16195134

Group type: EXPERIMENTAL
Intervention: Moclobemide (400 mg/day)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Clomipramine (150 mg/day)
Number of subjects: 115
Study: 11900100

Group type: EXPERIMENTAL
Intervention: Humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pigeons
Number of subjects: 0
Study: 9713084

Group type: EXPERIMENTAL
Intervention: Percutaneous mitral balloon valvuloplasty
Number of subjects: 88

Group type: COMPARATOR
Intervention: Open commissurotomy
Number of subjects: 88
Study: 8040443

Group type: EXPERIMENTAL
Intervention: CT during arterial portography (CTAP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Short tau inversion recovery MRI (STIR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CTAP
Number of subjects: 40

Group type: COMPARATOR
Intervention: STIR MRI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CTAP and STIR MRI
Number of subjects: 40
Study: 3394908

Group type: EXPERIMENTAL
Intervention: Diazepam in propylene glycol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam in lipid formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam in mixed micelles
Number of subjects: 12
Study: 11694683

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Traditional care (control)
Number of subjects: 746
Study: 30740748

Group type: EXPERIMENTAL
Intervention: Gabapentin (maximum daily dose of 900 mg)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Baclofen (maximum daily dose of 60 mg)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 234

Group type: COMPARATOR
Intervention: Baclofen
Number of subjects: 234
Study: 29964036

Group type: EXPERIMENTAL
Intervention: Genotypic resistance-guided therapy for 14 days (n=21 in trial 1, n=205 in trial 2)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Empirical therapy for 14 days (n=20 in trial 1, n=205 in trial 2)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Doxycycline sequential therapy (part of trial 1)
Number of subjects: 441
Study: 26908153

Group type: EXPERIMENTAL
Intervention: Home visits from a Visual Rehabilitation Officer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 30
Study: 24443851

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60
Study: 22915637

Group type: EXPERIMENTAL
Intervention: DAS 100 mg/day
Number of subjects: 253

Group type: COMPARATOR
Intervention: IM 400 mg/day
Number of subjects: 253
Study: 19906525

Group type: EXPERIMENTAL
Intervention: SIS plus reflexology
Number of subjects: 183

Group type: COMPARATOR
Intervention: SIS plus scalp massage (control)
Number of subjects: 183
Study: 16842931

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 0
Study: 14999212

Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 59
Study: 11581440

Group type: EXPERIMENTAL
Intervention: OROS MPH once a day (qd)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (IR MPH) 3 times a day (tid)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: IR MPH tid
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: OROS MPH qd
Number of subjects: 282
Study: 9842765

Group type: COMPARATOR
Intervention: Normal speed condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fast speed condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Huntington's disease subjects
Number of subjects: 0
Study: 7986459

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 19
Study: 2646838

Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Computer-assisted contour detection system (CAAS)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Premedication with 10 mg isosorbide dinitrate sublingually
Number of subjects: 396
Study: 29370485

Group type: EXPERIMENTAL
Intervention: Maudsley Staging Method (MSM)
Number of subjects: 643
Study: 28281196

Group type: EXPERIMENTAL
Intervention: Inhalation via I‐neb®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation via Turbuhaler®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation via new dry powder inhaler (new DPI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation via Spira®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Predicted lung deposited dose
Number of subjects: 0
Study: 26651465

Group type: EXPERIMENTAL
Intervention: Internet-based recovery training (6 sessions)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Internet-based recovery training
Number of subjects: 128

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 128
Study: 24565484

Group type: EXPERIMENTAL
Intervention: Auvi-Q
Number of subjects: 693

Group type: COMPARATOR
Intervention: EpiPen
Number of subjects: 693
Study: 22030760

Group type: EXPERIMENTAL
Intervention: non-RS protocol
Number of subjects: 41

Group type: COMPARATOR
Intervention: RS protocol
Number of subjects: 41
Study: 18444532

Group type: EXPERIMENTAL
Intervention: Oral captopril (25 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral nicardipine (20 mg)
Number of subjects: 50
Study: 17160221

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team approach in a Diabetes Center (DC)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Endocrinologist-only approach
Number of subjects: 205
Study: 14979419

Group type: EXPERIMENTAL
Intervention: Controllable perfusion-related variables during CPB (e.g., hematocrit, mean arterial pressure, thermic perfusion, blood lactate, colloid osmotic pressure, pulsatile perfusion, acid base homeostasis, oxygenation, coated circuitry)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mortality Assessment Perfusion Score (MAPS)
Number of subjects: 0
Study: 10548210

Group type: EXPERIMENTAL
Intervention: PCA with a bolus of 1.5 mg piritramide and a 10-min lockout interval
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PCA combined with nonsteroidal anti-inflammatory drugs prescribed three times per day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional nurse-controlled analgesia
Number of subjects: 120
Study: 10999062

Group type: EXPERIMENTAL
Intervention: Captopril therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 30
Study: 1899325

Group type: EXPERIMENTAL
Intervention: Theophylline (250 mg three or four times a day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6350401

Group type: EXPERIMENTAL
Intervention: Captopril (n = 50)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (n = 42)
Number of subjects: 92
Study: 31638455

Group type: EXPERIMENTAL
Intervention: Huperzine A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30314833

Group type: EXPERIMENTAL
Intervention: Distal Radial (DR) approach
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional Radial (TR) approach
Number of subjects: 200
Study: 28740972

Group type: EXPERIMENTAL
Intervention: PTFE spacer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cotton spacer
Number of subjects: 50
Study: 26906629

Group type: EXPERIMENTAL
Intervention: Commercial open-group behavioural weight-loss programme
Number of subjects: 23
Study: 25161043

Group type: EXPERIMENTAL
Intervention: Pharmaco-invasive (PI) strategy
Number of subjects: 1884

Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 1884
Study: 22149452

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (100 mmol daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 21
Study: 18022292

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: High midlife total cholesterol (TC)
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Decrease in TC over time
Number of subjects: 1382

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1382
Study: 17079070

Group type: EXPERIMENTAL
Intervention: VLRP with rhabdosphincter reconstruction (VLRP-R)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard VLRP
Number of subjects: 62
Study: 15859523

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11886688

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75-225 mg/day
Number of subjects: 301

Group type: COMPARATOR
Intervention: Fluoxetine 20-60 mg/day
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 10074873

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study: 7673949

Group type: COMPARATOR
Intervention: Chlorambucil (0.1 mg/kg/day orally for 12 months)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Chlorambucil + Plasma Exchange (15 courses during the first 4 months)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 2169778

Group type: EXPERIMENTAL
Intervention: Granisetron (40-200 micrograms/kg, 30 min infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granisetron (160 micrograms/kg, 3 min infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granisetron (up to 160 micrograms/kg b.d. for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6785059

Group type: EXPERIMENTAL
Intervention: Aciclovir
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Trifluorothymidine (TFT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups (Aciclovir and TFT)
Number of subjects: 38
Study: 31179485

Group type: EXPERIMENTAL
Intervention: Letermovir prophylaxis
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study: 28197938

Group type: EXPERIMENTAL
Intervention: Taohong Siwu Decoction (TSD) plus oral prednisone
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo plus oral prednisone
Number of subjects: 148
Study: 29231407

Group type: EXPERIMENTAL
Intervention: Long-snake moxibustion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Warm needling
Number of subjects: 120

Group type: COMPARATOR
Intervention: Western medication (methotrexate)
Number of subjects: 120
Study: 24439349

Group type: EXPERIMENTAL
Intervention: Proactive e‐referral to Decide2Quit.org
Number of subjects: 1814

Group type: COMPARATOR
Intervention: Paper referrals to Decide2Quit.org
Number of subjects: 1814
Study: 22459966

Group type: EXPERIMENTAL
Intervention: Eritoran 4 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Eritoran 12 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Eritoran 28 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Eritoran (all doses)
Number of subjects: 64
Study: 20855800

Group type: EXPERIMENTAL
Intervention: Palifermin (180 µg per kg of body weight) administered intravenously as a single dose 3 days before each chemotherapy cycle (maximum, 6 cycles)
Number of subjects: 48
Study: 18249119

Group type: EXPERIMENTAL
Intervention: Chemotherapy (various agents and schedules)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Chemotherapy clinical trial
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Chemotherapy in patients over 60 years
Number of subjects: 828
Study: 15979448

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 12915290

Group type: EXPERIMENTAL
Intervention: Olanzapine 5-15 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10952748

Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Passive flexion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ritchie pain score
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Swelling
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Arthritis Impact Measurements Scales question about buttoning clothes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Visual analogue scale questions about activity of the disease
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Visual analogue scale questions about swelling of the joint
Number of subjects: 21
Study: 8970781

Group type: EXPERIMENTAL
Intervention: Semipermeable glove
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard cotton glove
Number of subjects: 46
Study: 1580295

Group type: EXPERIMENTAL
Intervention: Topical vitamin E
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 18
Study: 6374682

Group type: EXPERIMENTAL
Intervention: miconazole/hydrocortisone preparation
Number of subjects: 62

Group type: COMPARATOR
Intervention: nystatin/benzalkonium chloride/dimethicone/hydrocortisone preparation
Number of subjects: 62
Study: 2876035

Group type: EXPERIMENTAL
Intervention: Latamoxef 6g daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latamoxef 3g daily for 7 days
Number of subjects: 0
Study: 30569673

Group type: EXPERIMENTAL
Intervention: SuperPATH approach
Number of subjects: 24

Group type: COMPARATOR
Intervention: posterolateral approach
Number of subjects: 24
Study: 26538525

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide group (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg)
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate group (previous regimens)
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide group
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate group
Number of subjects: 1443
Study: 25547513

Group type: EXPERIMENTAL
Intervention: On-line educational intervention to improve financial abuse detection (n = 78)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no on-line educational intervention, n = 76)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: On-line educational intervention
Number of subjects: 154
Study: 22697193

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (LAI)
Number of subjects: 369
Study: 20420113

Group type: EXPERIMENTAL
Intervention: Ginger (1 gram of dried powder suspended in 100 ml water)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 14
Study: 18689435

Group type: EXPERIMENTAL
Intervention: Autologous olfactory ensheathing cell transplantation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Transplant recipient
Number of subjects: 6
Study: 15659136

Group type: EXPERIMENTAL
Intervention: Steroid avoidance (SA) with basiliximab, cyclosporine (CsA), and mycophenolate mofetil (MMF)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Steroid avoidance (SA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group with steroids tapered to 5 mg prednisone/d by day 30
Number of subjects: 77
Study: 12929057

Group type: EXPERIMENTAL
Intervention: TSC-EGD
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PSC-EGD
Number of subjects: 150

Group type: COMPARATOR
Intervention: C-EGD
Number of subjects: 150
Study: 11125660

Group type: EXPERIMENTAL
Intervention: Leader briefings
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Team-interaction training
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Novel environments
Number of subjects: 237

Group type: COMPARATOR
Intervention: Routine environments
Number of subjects: 237
Study: 8931612

Group type: EXPERIMENTAL
Intervention: Health education program delivered by female Cherokee lay health educators
Number of subjects: 996

Group type: COMPARATOR
Intervention: Control group (no education program)
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 996
Study: 1327609

Group type: EXPERIMENTAL
Intervention: Sinemet CR 50/200
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sinemet STD 25/100
Number of subjects: 84
Study: 2997387

Group type: EXPERIMENTAL
Intervention: Intranasal high-dose interferon
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intranasal low-dose interferon
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 30892615

Group type: EXPERIMENTAL
Intervention: Maximum Advancement (MA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Incremental Advancement (IA)
Number of subjects: 48
Study: 30222122

Group type: EXPERIMENTAL
Intervention: Left distal transradial approach (ldTRA)
Number of subjects: 200
Study: 27070229

Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 55

Group type: COMPARATOR
Intervention: Wavefront-optimized LASIK
Number of subjects: 55
Study: 25236994

Group type: EXPERIMENTAL
Intervention: Active treatment (sunitinib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 22358993

Group type: EXPERIMENTAL
Intervention: TACE with multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, 5-fluorouracil)
Number of subjects: 51

Group type: COMPARATOR
Intervention: TACE with epirubicin
Number of subjects: 51
Study: 20163368

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg (Group B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (Group B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ranibizumab (Group A)
Number of subjects: 88
Study: 17403436

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (n = 9)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single-agent and combined treatments
Number of subjects: 16

Group type: COMPARATOR
Intervention: Combined therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Metformin (n = 6)
Number of subjects: 16